期刊文献+

细胞周期蛋白激酶抑制剂flavopiridol对骨肉瘤耐药细胞MG63/ADR增殖抑制的体内外实验研究

Inhibitory Effects of CDKI on MG63/ADR Cells Proliferation both in vitro and in vivo
下载PDF
导出
摘要 目的探讨细胞周期蛋白激酶抑制剂(flavopiridol)在体内外抑制骨肉瘤耐阿霉素细胞株MG63/ADR增殖的作用及其机制。方法四甲基偶氮唑蓝法(MTT法)测定细胞增殖抑制率。流式细胞计数法测量flavopiridol给药后MG63/ADR细胞周期的变化及凋亡率。免疫印迹法(Western-blot)检测细胞中pro-caspase-9、pro-caspase-3、caspase-8、Bcl-2、Bcl-xL、p53、Bax及活化型多聚ADP核糖多聚酶(PARP-85)蛋白的表达。采用MG63/ADR建立荷瘤裸鼠模型,FP腹腔内给药,测量肿瘤体积及裸鼠体质量变化,计算肿瘤抑制率。结果 Flavopiridol可抑制骨肉瘤耐阿霉素细胞株MG63/ADR的细胞增殖,其效果呈时间及浓度依赖性。Flavopiridol给药后,耐药细胞株MG63/ADR的细胞凋亡率明显高于对照组(P<0.05)。Flavopiridol给药后,耐药细胞株中的pro-caspase-9、pro-caspase-3、Bcl-2以及Bcl-xL的表达下降,活化型caspase-8、PARP-85的表达增加。Flavopiridol可有效抑制荷瘤小鼠体内耐药骨细胞的生长。结论细胞周期蛋白激酶抑制可在体外及体内有效抑制骨肉瘤耐药细胞株的增殖,其机制可能与死亡受体介导的caspase信号传导途径及非p53介导的线粒体凋亡信号传导途径相关。 Objective To investigate the growth-inhibition and apoptosis effects of flavopiridol on human osteosareoma MG63/ADR cell and the related mechanism both in vitro and in vivo. Methods The proliferation of MG63 and MG63/ADR cells was determined by using MTT method. Cell cycle progression and apoptosis ratio were determined by flow cytometry. The expressions of pro-easpase-9, pro-caspase-3, cas- pase-8, Bcl-2, Bel-xL, p53, Bax and cleaved-PARP were detected by Western blot. The subcutaneous tumors of MG63/ADR cells were also established in nude mice to study the antitumor effects of flavopiridol. Results After exposure to flavopiridol,the growth of MG63/ADR cells were inhibited in a time- and dose-dependent manner. Apoptosis rate of MG63/ADR was higher than control group ( P 〈0.05 ). The ex- pressions of pro-caspase-9, pro-casepase-3, Bcl-2 and Bcl-xL were down-regulated, and the expression of active-form PARP and active-form caspase-8 were up-regulated. The expressions of p53 and Bax were not affected. The in vivo inhibitory effect on ADR clones of osteosarcoma in the treatment group was observed compared with the control group. Conclusion Flavopiridol can inhibit the growth of drug-resistant os- teosarcoma cells both in vitro and vivo. The apoptosis of MG63/ADR cells induced by flavopiridol might via easpase cascade pathway and p53-independent mitochondrial apeptosis pathway.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2012年第11期968-971,976,共5页 Journal of China Medical University
基金 国家自然科学基金资助项目(30973021)
关键词 FLAVOPIRIDOL 细胞周期 骨肉瘤 凋亡 CASPASE flavopiridol cell cycle osteosarcoma apoptosis caspase
  • 相关文献

参考文献13

  • 1Hawkins DS,Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy [ J ]. Cancer, 2003,98 ( 11 ) : 2447-2456. 被引量:1
  • 2Janeway KA,Grier HE. Sequelae of osteosarcoma medical therapy :areview of rare acute toxicities and late effects, [j]. Lancet Oncol,2010,11(7):670-678. 被引量:1
  • 3Li X,Tanaka K,Nakatani F,et al. Transactivation of cyclin E gene byEWS - Flil and antitumor effects of cyclin dependent kinase in -hibitor on Ewing ’ s family tumor cells [ J ] ? Int J Cancer,2005,116(3):385-394. 被引量:1
  • 4范姝丽,李旭,林杰,白小涓.Flavopiridol诱导耐阿霉素尤文肉瘤细胞株VH-64/ADR凋亡及作用机制的研究[J].现代肿瘤医学,2009,17(8):1407-1410. 被引量:1
  • 5Okada T,Tanaka K,Nakatani F,et al. Involvement of P-glycoproteinand MRP1 in resistance to cyclic tetrapeptide subfamily of histonedeacetylase inhibitors in the drug-resistant osteosarcoma and Ewing ’s sarcoma cells [ J ]. Int J Cancer,2006,118 (1): 90-97. 被引量:1
  • 6Billard C,Menasria F,Quiney C,et a 1 .Flavopiridol-induced iNOSdownregulation during apoptosis of chronic lym phocytic leukemiacells is caspase-dependent[ J]. Leuk Res,2008,32(5) :755-760. 被引量:1
  • 7Dickson MA,Schwartz GK. Development of cell-cycle inhibitors forcancer therapy[J]. Curr Oncol,2009,16(2) :36-43. 被引量:1
  • 8Bansal T,Jaggi M,Khar RK,et al. Emerging significance of flavonoidsas P-glycoprotein inhibitors in cancer chemotherapy [J ]. J Pharm PharmSci’2009’12(1):46-78. 被引量:1
  • 9Krishna S,Low IC,Pervaiz S.Regulation of mitochondrial metabolism :yet another facet in the biology of the oncoprotein Bcl-2 [ J ] .BiochemJ,2011,435(3):545-551. 被引量:1
  • 10Rosato RR,Almenara JA,Kolia SS.Mechanism and functional roleof XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat an-tileukemic interactions[ j].Mol CancerTher,2007,6(2):692-702. 被引量:1

二级参考文献12

  • 1李旭,范姝丽,李岩,朱悦,屠冠军,范广宇.Flavopiridol对尤文肉瘤SK-N-MC细胞增殖的抑制作用[J].中华骨科杂志,2007,27(7):534-538. 被引量:2
  • 2de Alava E,Gerald WL.Molecular biology of the Ewing's sarcoma/ primitive neuroectodermal tumor family[J].J Clin Oncol,2000,18:204-213. 被引量:1
  • 3Shankar AG,Ashley S,Craft AW,et al.Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma[J].Med Pediatr Oncol,2003,40:141-147. 被引量:1
  • 4Li X,Tanaka K,Nakatani F,et al.Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells[J].Int J Cancer,2005,116:385-394. 被引量:1
  • 5Okada T,Tanaka K,Nakatani F,et al.Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells[J].Int J Cancer,2006,118:90-97. 被引量:1
  • 6Ambudkar SV,Kimchi-Sarfaty C,Sauna ZE,et al.P-glycoprotein:from genomics to mechanism[J].Oncogene,2003,22:7468-7485. 被引量:1
  • 7Boerner SA,Tourne ME,Kaufmann SH,et al.Effect of P-glycoprotein on flavopiridol sensitivity[J].Br J Cancer,2001,84:1391-1396. 被引量:1
  • 8Hooijberg JH,Broxterman HJ,Scheffer GL,et al.Potent interaction of flavopiridol with MRP1[J].Br J Cancer,1999,81:269-276. 被引量:1
  • 9Witters LM,Myers A,Lipton A.Combining flavopiridol with various signal transduction inhibitors[J].Oncol Rep,2004,11(3):693-698. 被引量:1
  • 10Ruefli AA,Johnstone RW.A role for P-glycoprotein in regulating cell growth and survival[J].Clin and Applied Immunol,2003,4:31-47. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部